147 related articles for article (PubMed ID: 38074469)
1. Structural insight into the macrocyclic inhibitor TPX-0022 of c-Met and c-Src.
Qu L; Lin H; Dai S; Guo M; Chen X; Jiang L; Zhang H; Li M; Liang X; Chen Z; Wei H; Chen Y
Comput Struct Biotechnol J; 2023; 21():5712-5718. PubMed ID: 38074469
[TBL] [Abstract][Full Text] [Related]
2. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
Repetto M; Crimini E; Ascione L; Boscolo Bielo L; Belli C; Curigliano G
Invest New Drugs; 2022 Oct; 40(5):1133-1136. PubMed ID: 35612671
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
4. Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring
Wang C; Li J; Qu L; Tang X; Song X; Yang F; Chen X; Lin Q; Lin W; Zhou Y; Tu Z; Chen Y; Zhang Z; Lu X
J Med Chem; 2022 Nov; 65(22):15140-15164. PubMed ID: 36355693
[No Abstract] [Full Text] [Related]
5. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
6. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors.
Qu L; Chen X; Wei H; Guo M; Dai S; Jiang L; Li J; Yue S; Chen Z; Chen Y
Commun Chem; 2022 Jan; 5(1):5. PubMed ID: 36697561
[TBL] [Abstract][Full Text] [Related]
8. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
9. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
11. c-Src binds to the cancer drug Ruxolitinib with an active conformation.
Duan Y; Chen L; Chen Y; Fan XG
PLoS One; 2014; 9(9):e106225. PubMed ID: 25197973
[TBL] [Abstract][Full Text] [Related]
12. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles.
Georghiou G; Kleiner RE; Pulkoski-Gross M; Liu DR; Seeliger MA
Nat Chem Biol; 2012 Feb; 8(4):366-74. PubMed ID: 22344177
[TBL] [Abstract][Full Text] [Related]
13. Ameliorative effects of mangiferin derivative TPX on insulin resistance via PI3K/AKT and AMPK signaling pathways in human HepG2 and HL-7702 hepatocytes.
Fan X; Jiao G; Pang T; Wen T; He Z; Han J; Zhang F; Chen W
Phytomedicine; 2023 Jun; 114():154740. PubMed ID: 36965373
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
15. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
[TBL] [Abstract][Full Text] [Related]
16. The Campylobacter jejuni thiol peroxidases Tpx and Bcp both contribute to aerotolerance and peroxide-mediated stress resistance but have distinct substrate specificities.
Atack JM; Harvey P; Jones MA; Kelly DJ
J Bacteriol; 2008 Aug; 190(15):5279-90. PubMed ID: 18515414
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa thiol peroxidase protects against hydrogen peroxide toxicity and displays atypical patterns of gene regulation.
Somprasong N; Jittawuttipoka T; Duang-Nkern J; Romsang A; Chaiyen P; Schweizer HP; Vattanaviboon P; Mongkolsuk S
J Bacteriol; 2012 Aug; 194(15):3904-12. PubMed ID: 22609922
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo M; Dai S; Wu D; Duan Y; Li J; Qu L; Jiang L; Chen Z; Chen X; Chen Y
Bioorg Med Chem Lett; 2021 Feb; 34():127757. PubMed ID: 33359446
[TBL] [Abstract][Full Text] [Related]
19. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
20. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
